Prostate_specific_antigen_in_the_management_of_patients_with_localized_adenocarcinoma_of_the_prostate_treated_with_primary_radiation_therapy._The_records_of_143_patients_treated_at_5_institutions_with_external_beam_megavoltage_irradiation_for_localized_prostatic_cancer_were_reviewed_to_evaluate_post-treatment_changes_in_prostate_specific_antigen_(PSA)_in_the_context_of_subsequent_events._Complete_responders_were_defined_as_patients_clinically_well_with_normal_PSA,_clinical_failures_were_patients_with_documented_local_tumor_recurrence_or_distant_metastases_and_chemical_failures_were_patients_clinically_well_but_with_a_PSA_level_above_the_upper_limits_of_normal._Correlations_with_pre-treatment_PSA_values_were_also_made_for_the_50_of_143_patients_for_whom_pre-treatment_PSA_data_were_available._Median_patient_followup_was_27_months_(range_18_to_91_months)._The_data_were_analyzed_with_parametric_and_nonparametric_univariate_and_multivariate_statistical_procedures._Pre-treatment_PSA_levels_increased_with_increasing_tumor_stage_(p_=_0.004)_but_not_with_increasing_summed_Gleason_pattern_scores_(p_=_0.15)._The_probability_of_remaining_a_complete_responder_decreased_with_increasing_stage_(p_=_0.008)_but_not_with_increasing_Gleason_score_(p_=_0.14)._Increasing_pre-treatment_PSA_correlated_with_clinical_failure_(p_=_0.01)_and_chemical_failure_(p_=_0.006)._Of_the_patients_with_a_pre-treatment_PSA_level_of_less_than_4_times_the_upper_limits_of_normal_83%_remained_as_complete_responders_compared_to_30%_of_those_with_a_higher_pre-treatment_PSA_(p_=_0.0002)._The_return_of_PSA_levels_to_the_normal_range_within_6_months_after_treatment_was_strongly_correlated_with_a_favorable_outcome_when_analyzed_by_multivariate_logistic_regression._The_status_at_last_followup_of_patients_who_had_a_normal_PSA_level_at_6_months_versus_those_with_an_elevated_PSA_level_6_months_after_treatment_is_94%_versus_8%_for_complete_responders_(p_=_0.0001),_0%_versus_60%_for_clinical_failures_(p_=_0.002)_and_6%_versus_32%_for_chemical_failures_(p_=_0.14)._Similar_results_occurred_when_analyzing_outcomes_in_relationship_to_PSA_normalization_within_12_months_after_treatment_(p_=_0.001_for_clinical_failures,_p_=_0.02_for_chemical_failures_and_p_=_0.001_for_complete_responders)._We_conclude_that_the_pre-treatment_level_of_PSA_is_an_independent_prognostic_factor_for_prostate_cancer_patients_treated_with_primary_radiation_therapy,_and_that_the_failure_of_PSA_to_return_to_the_normal_range_within_1_year_after_completion_of_treatment_identifies_a_group_of_patients_at_high_risk_for_tumor_recurrence.